معرفی
Nisha A Mohindra, MD is an Associate Professor at Northwestern University's Feinberg School of Medicine with dual appointments in the Department of Medicine (Hematology and Oncology) and Department of Surgery. She maintains clinical affiliations with Northwestern Memorial Hospital and Jesse Brown VA Medical Center, and participates in multiple research centers including the Institute for Public Health and Medicine (IPHAM), Northwestern University Clinical and Translational Sciences Institute (NUCATS), and the Robert H. Lurie Comprehensive Cancer Center.
Dr. Mohindra completed her medical degree at the University of Texas/Southwestern in 2009, followed by residency in Internal Medicine (2012) and fellowship in Hematology-Oncology (2015), both at Northwestern University's Feinberg School of Medicine. She is board certified in both Internal Medicine and Medical Oncology by the American Board of Internal Medicine.
Her research focuses on critical areas in oncology including Healthcare Quality, Health Disparities, Health Services Research, Lung Cancer, Medical Decision Making, Patient-Centered Care, and Patient-Reported Outcomes. Dr. Mohindra's work particularly emphasizes improving outcomes for patients with lung cancer through better understanding of treatment toxicities and implementation of patient-centered decision-making tools.
Analysis of her recent publications reveals a strong focus on lung cancer therapeutics, immunotherapy-related toxicities, and implementation of patient-reported outcomes in clinical practice. Her work spans clinical trials, guideline development, and health services research with an emphasis on translating research findings into practical clinical applications.
Dr. Mohindra serves as principal investigator for multiple active clinical trials including the LCRF Leader Trial (LCMC4) evaluating actionable drivers in early-stage lung cancer, a Phase 1/1b study of ORIC-114 in patients with advanced solid tumors harboring EGFR or HER2 alterations, and a randomized Phase III study comparing osimertinib with and without bevacizumab for metastatic EGFR-mutant non-small cell lung cancer.
Professional relationships include consulting and advisory work for AstraZeneca and Regeneron Pharmaceuticals, Inc., reflecting her expertise in oncology therapeutics and clinical practice. Her position as a contributing author to NCCN Guidelines demonstrates recognition as a thought leader in cancer care standards.
